Xarelto Cases Heading to Trial
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
There are rare times when you get the opportunity to be part of legal history. As a member of the Bellwether Committee for Xarelto cases, I am assisting with the charge to make this multi district litigation a historic landmark of justice.
Xarelto has been responsible for numerous deaths and horrible side effects. It was introduced by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals in 2011, as part of a new generation of anticoagulants promoted as a superior alternative to Coumadin (warfarin), which has been the go-to blood thinner for prevention of strokes among patients with atrial fibrillation for a decade. Currently, there are approximately 13 million active prescriptions.
While all blood thinners carry a risk of bleeding problems, Xarelto lacks an approved antidote that doctors can use to reverse the effects of the drug. While doctors can quickly stop the blood thinning effects of warfarin, users of Xarelto have reported experiencing uncontrollable bleeding that physicians were unable to stop, often leading to severe injury or death.
Finally, plaintiffs awaiting justice for years after experiencing the devastating effects of Xarelto are closer to their day in court. August has been a whirlwind of activity. There are four trials slated for February of 2017. Discovery, arguments and strikes have already been completed in all four trials. We have been pushing to make sure that Bayer along with Janssen Pharmaceuticals understands the gravity of their actions, and that most people should have never switched from warfarin in the first place.
The new science is also supporting our claims that Xarelto is not better than warfarin, and it is actually worse in many cases. The newest study done by the Institute For Safe Medication Practices (ISMP) examined all the adverse events reported to the FDA after patients took the coagulant. They determined that Xarelto failed to prevent pulmonary embolism, caused uncontrollable bleeding, and wasn’t very efficient.
The most troubling piece of information uncovered was 80.9% of the complaints made to the FDA involved an adverse bleeding event, and there were 1,121 deaths.
At The Michael Brady Lynch Firm, we take these bleeding side effects very seriously, and we fight to make sure that pharmaceutical companies understand the seriousness as well. If you or a loved one have experienced a bleeding event from taking Xarelto, I urge you to contact us at 877-513-9517. Let us fight for you.